AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00648063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole Tablets 2.5 mg
Description: 2.5mg, single dose fasting
Study NCT00648063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femara® Tablets 2.5 mg
Description: 2.5mg, single dose fasting
Study NCT05515965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: The mechanical correction method of taping to the Kinesiotape group was used. In rheumatoid hand patients, due to the presence of a deformity called hitchhiker's finger, the thumb is taped with 50-75% tension to create a pulling force in the direction of flexion and abduction. The application was performed with the patient in a sitting position with his arm supported by a pillow from the elbow. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
Study NCT05515965 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham application was applied to both dominant and nondominant hands in Control Group patients. Sham taping is the bonding of I tape to the 1st finger without tension and does not contain any features. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
Study NCT02405078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Given standard salvage chemotherapy
Study NCT02294227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to secukinumab was also available in 1.0 mL liquid formulation in prefilled syringe to match the active drug.
Study NCT02679352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMR Stemless
Description: Total anatomic or reverse shoulder arthroplasty
Study NCT01656382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABLC
Study NCT01656382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABLC
Study NCT00126373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Wellbutrin (bupropion)
Description: bupropion 150mg-300mg daily
Study NCT00126373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wellbutrin (bupropion)
Description: bupropion 150mg-300mg daily
Study NCT02175251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high frequency (20Hz)
Description: 10 session in 5 days with high frequency (20 Hz)
Study NCT02175251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low frequency (1Hz)
Description: 10 session in 5 days with low frequency (1Hz)
Study NCT02175251 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: 10 session in 5 days with sham-controlled
Study NCT04927182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Exercise Training (Age Group 1; Young adult 17 -30 years)
Description: Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
Study NCT02405078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG-PET/CT scan
Study NCT02405078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET/CT scan
Study NCT02405078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET/CT scan
Study NCT03712696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIGNICAP™
Description: Scalp cooling to prevent chemotherapy-induced alopecia
Study NCT00265993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: * All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days.~* Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months.
Study NCT03384615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-Focused Therapy
Description: CFT for PGD symptoms in the present project is inspired by two well-established CFT treatment manuals. The first is used for treatment of PTSD (Lee \& James, 2011) and the other for treatment of anger (Kolt, 2011). The manual for CFT for PGD adopts both structure and techniques from these into an 8-week, group-based program with weekly 2 1/4-hour sessions. Each session contains elements of psychoeducation on uncomplicated and prolonged grief reactions, identifying unhelpful strategies for self-protection and facilitating use of more helpful strategies, and training an open and compassionate management of grief-related distress through CFT exercises. Between the sessions the participant will train the exercises introduced at the previous session.
Study NCT04927182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Exercise Training (Age Group 2; 31 to 45 years)
Description: Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
Study NCT04927182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Exercise Training (Age Group 3; Above 45 years)
Description: Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
Study NCT04703231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of macular thickness, corneal thickness and lens opacities
Description: The incidence of macular thickness, Corneal thickness, intraocular pressure and lens opacities will be investigated by an ophthalmologist.
Study NCT02701140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stenting
Description: Within 1h after the first PCI, patients will be randomized to either ticagrelor or clopidogrel.
Study NCT02701140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary ECG recording
Description: Measurement of ST segment elevation using intracoronary ECG recording
Study NCT02701140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Flow reserve
Description: measured with an intracoronary pressure/temperature sensor-tipped guidewire
Study NCT02701140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Index of Microcirculatory Resistance
Description: measured with an intracoronary pressure/temperature sensor-tipped guidewire
Study NCT02701140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Flow Reserve
Description: measurement of Fractional Flow Reserve during hyperemic phase.
Study NCT02927600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI Breakfast
Description: Intake of low GI breakfast
Study NCT02927600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI Breakfast
Description: Intake of high GI breakfast
Study NCT02927600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI Dinner
Description: Intake of Low GI dinner
Study NCT02927600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI Dinner
Description: Intake of high GI dinner
Study NCT03453320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin solution
Description: Infusion rate and effects
Study NCT00038974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Study NCT00038974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT01904123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01904123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01904123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAT3 Inhibitor WP1066
Description: Given PO
Study NCT00475930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate (CHG) impregnated cloths
Description: self applied three times per week
Study NCT00475930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comfort Bath cloths (placebo cloths)
Description: self applied three times weekly
Study NCT00561054 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: CETUXIMAB
Description: 400 mg/m2 starting dose, 250 mg/m2 weekly dose
Study NCT00824161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-109
Description: 14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.~Number of cycles: until unacceptable toxicity or disease progression requires discontinuation.
Study NCT02084745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Boston keratoprosthesis type 1
Description: The Boston KPro, purchased from Massachusetts Eye and Ear infirmary (Boston, MA), is implanted using the usual standard technique.
Study NCT02084745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma drainage device
Description: The GDD that will be used is the Ahmed implant (New World Medical, Rancho Cucamonga, CA). The Ahmed implant will be implanted using the standard technique either at the time of KPro surgery in group 1, or 6 months following KPro in group 2.
Study NCT03151096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: one pill of Riboflavin will be taken orally with water
Study NCT03151096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one pill of placebo will be taken orally with water
Study NCT02892344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QMF149 150/80 μg
Description: QMF149 150/80 μg o.d via Concept1
Study NCT02892344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MF 200 μg
Description: MF 200 μg o.d. via Twisthaler®
Study NCT03520829 — intervention group
Intervention type: DEVICE
Intervention: Intuitive Plan
Description: dosimetric planning software
Study NCT02553226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
Study NCT02553226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
Study NCT02611297 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryoprobe
Study NCT02628288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Bifurcation PCI
Description: In one group, the coronary bifurcation lesion will be treated (Coronary bifurcation PCI) with the Axxess device + Absorb BVS. In the other group, the coronary bifurcation lesions will be treated(Coronary bifurcation PCI) by modified T stenting using Absorb BVS.
Study NCT01398722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive insulin therapy
Description: Titration of the IV insulin rate for glucose goal 110-150 mg/dL
Study NCT01398722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional insulin therapy
Description: Titration of the IV insulin rate for glucose goal 150-180 mg/dl
Study NCT00491829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg qhs
Description: flibanserin 50 mg
Study NCT00491829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg
Description: flibanserin 100mg
Study NCT00491829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01636960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIFN alfa-2b
Study NCT03139110 — intervention group
Intervention type: BEHAVIORAL
Intervention: Presence of a mediator in the emergency departments
Description: The mediator tasks are :~* Be available to patients who can solicit him and respond to their requests for information, in particular on the organization of the emergency departments and on waiting times~* Have a proactive attitude towards patients showing nervousness signs~* Report patients expressing the will to leave the emergency departments before medical care~* Manage conflicts between patients / accompanying persons and emergency staff and also between patients.
Study NCT04932668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feasibility and Impact of Home-based Electrical Stimulation Program
Description: Home-based NMES program on spastic leg. The NMES pre-programmed dosage (locked):~NMES waveform is biphasic PC, Frequency 50Hz, pulse width 400µs, ON:OFF 10s:20s and current amplitude: individual maximum tolerated to achieve ankle dorsiflexion.
Study NCT04044274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOPstim
Description: IOPstim (IMEDOS, Jena, Germany) is a device exerting defined pressure to the sclera and hence increasing IOP.
Study NCT04044274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction Cup
Description: Suction Cup is a device exerting defined suction to the clear and hence increasing IOP
Study NCT01542931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Description: Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
Study NCT00419666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol 3mcg/g
Description: Calcitriol 3mcg/g ointment applied twice daily for 56 weeks.
Study NCT01538927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant
Description: Fibrin Sealant 4ml (Baxter Tisseel)
Study NCT01538927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suture
Description: Black silk 000
Study NCT01248091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nitroprusside Gel
Description: 10 cc nitroprusside gel
Study NCT01248091 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: half of the subjects will receive nitroprusside gel for IUD insertion and the other half will receive a placebo gel.
Study NCT03034304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MASCT-I
Description: The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
Study NCT03034304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 2g/m2/d, intravenous drip for 30min. Administration is conducted for continuous 5 days. After 4 weeks, the above cycle is repeated for 6 continuous cycles
Study NCT03034304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1 antibody
Description: 200 mg/every two weeks ,four weeks is a cycle. Subjects were treated with MASCT-I combined with PD1 antibody until disease progression, MASCT-I intolerance or study completion. If PD1 antibody intolerance occurs, MASCT-I therapy alone will continue. MASCT-I and PD1 antibody are adminnistered according to their respective drug cycle without interfering with each other.
Study NCT03034304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 60mg/m2, from the first day of each cycle, it is used for 1-2 days, intravenous drip. Repeat the above cycle after 4 weeks, no more than 8 cycles
Study NCT03034304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2, Intravenous drip for about 30 min, used on the first and eighth days of each cycle, and every 3-4 weeks as a cycle
Study NCT03034304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70mg/m2, Use on the first day of each chemotherapy cycle, intravenous drip for 30-120 min, and every 3-4 weeks as a cycle;
Study NCT03034304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 5mg/ml/min, Use it on the first day of each chemotherapy cycle, intravenous drip for 30 minutes, and every 3-4 weeks as a cycle
Study NCT02318797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Self-Directed Care
Description: Patient self-management toolkits, web portal with information on health conditions, personal health care use data, health tracking tools and wellness programs
Study NCT02318797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider-Supported Integrated Care
Description: Registered nurse on staff at community mental health centers with access to patient-level physical health information to: 1) work with patients on coordinating their care, 2) enhance communication between providers and payer, and 3) provide patient wellness support and education
Study NCT02778711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: anti-IL-17
Study NCT03407820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable Chromic gut sutures
Description: In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received absorbable Chromic sutures are treated recording to the standard protocol and they are advised that they can start to gently rub the scab and suture line to encourage the sutures to fall off starting 10-14 days postoperatively.
Study NCT03407820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-absorbable Nylon sutures
Description: In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received Nylon sutures are treated recording to the standard protocol and sutures are removed after the usual time (10-14 days) of the received procedure.
Study NCT01127269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
Study NCT00940108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL425
Description: CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
Study NCT01892826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: 5000IU
Study NCT05466773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hemodialysis eating index (HDEI) base education intervention
Description: The investigators have developed the educational materials for patients, in order to improve the dialysis outcomes. The interventions will be delivered to patients and nurses in hospital based hemodialysis centers.
Study NCT01731509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fetal endoscopic tracheal occlusion
Description: FETO will be performed by placing a detachable balloon inside fetal trachea
Study NCT01731509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fetal endoscopic tracheal occlusion
Description: FETO will be performed by placing a detachable balloon inside fetal trachea
Study NCT03139357 — intervention group
Intervention type: OTHER
Intervention: GAD7, SF12, medical utilization, helpfulness questionnaire
Description: The questionnaires are administered to track stress level and medical utilization over a 2 year period.
Study NCT05822778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formaderm Dermal Filler Injection
Description: Dermal filler injection to facial areas
Study NCT05822778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q-MED RESTYLANE
Description: Dermal filler injection to facial areas
Study NCT05437185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
Study NCT05437185 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
Study NCT00519311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Intervention Package
Description: CHAP and Ask Diary